FOXO4-DRI vs NAD+
A side-by-side research comparison of FOXO4-DRI and NAD+ across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | FOXO4-DRI | NAD+ |
|---|---|---|
| Full name | FOXO4-D-Retro-Inverso Peptide (Senolytic) | Nicotinamide Adenine Dinucleotide (NAD+ / NMN / NR) |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | Research compound |
| Mechanism | Competitively disrupts FOXO4 sequestration of p53 in senescent cells, releasing p53 to trigger intrinsic apoptosis selectively in cells relying on this survival mechanism. | NAD+ serves as cofactor for sirtuins (SIRT1-7), PARPs (DNA repair), and CD38. Declining NAD+ impairs mitochondrial function and epigenetic maintenance. Restoration reactivates longevity pathways. |
| Molecular weight | ~4,500 Da | 663.4 Da |
| Half-life | 12-24 hours (D-amino acid stability) | 1-4 hours (IV), 4-8h (oral precursors) |
| Bioavailability | Moderate (SubQ) | 100% (IV), variable (oral 5-30%) |
| Typical dose | 5-10 mg/kg (animal studies) | 250-500mg IV or 500-1000mg NMN oral |
| Frequency | 3x per week for 3 weeks | Weekly (IV) or Daily (oral) |
| Route | Subcutaneous | IV infusion or Oral (precursors) |
FOXO4-DRI reported benefits
- Selective senescent cell elimination
- Potential aging reversal
- Improved tissue function
- Reduced inflammatory burden
- Hair regrowth (mice)
NAD+ reported benefits
- Restored cellular energy
- Enhanced DNA repair
- Sirtuin activation
- Improved mitochondrial function
- Cognitive clarity
- Anti-aging
Related comparisons
Research and educational reference only. Not medical advice.